Compare Aegon Ltd. (AEG) vs TG Therapeutics Inc (TGTX) Price & Performance

AEG trades at $9.415, down 0.37% on the day, with a bullish technical signal from moving averages. The company reported mixed recent earnings, beating expectations in Q2 and Q3 2025 but missing in Q4. Revenue for 2024 was $19.52 billion, with net income of $688 million. A dividend of $0.25 per share is scheduled for payment in July 2026. The balance sheet shows total assets of $327.39 billion and a declining debt-to-asset ratio, improving from 2.43 in 2020 to 1.46 in 2024.

AEG presents a moderate investment case with a low P/E of 13.54 and P/S of 0.57, suggesting potential undervaluation. Analyst sentiment is mixed with a 27.78% buy rating. Key risks include volatile cash flows and execution of strategic shifts, such as the relocation to the U.S. and partnership developments. The stock's outlook hinges on sustained profitability and successful implementation of corporate simplifications.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.